4.6 Review

COVID-19: progression of disease and intravascular coagulation - present status and future perspectives

Journal

CLINICAL CHEMISTRY AND LABORATORY MEDICINE
Volume 58, Issue 7, Pages 1029-1036

Publisher

WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2020-0502

Keywords

antibodies; anticoagulation; autopsy; coagulation parameters; COVID-19; D-dimer; disseminated intravascular coagulation; heparin; low-molecular-weight heparin; pulmonary embolism; SARS-CoV-2; thrombosis

Ask authors/readers for more resources

The timely and accurate diagnosis of infection with severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), remains the cornerstone of efforts to provide appropriated treatment for patients, to limit further spread of the virus and ultimately to eliminate the virus from the human society. We focus this article on (a) developments for improvement of diagnosis of specific SARS-CoV-2 virus, (b) laboratory changes in the immunologic and coagulation system, (c) therapeutic options for anticoagulant treatment of seriously affected patients and (d) on the perspectives through improvement of diagnostic and therapeutic medical procedures.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available